Swedish Orphan Biovitrum AB (publ)
STO:SOBI
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
239.4
346.4
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Swedish Orphan Biovitrum AB (publ)
Swedish Orphan Biovitrum AB (publ)
Total Liabilities & Equity
Swedish Orphan Biovitrum AB (publ)
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Total Liabilities & Equity
kr72.2B
|
CAGR 3-Years
16%
|
CAGR 5-Years
17%
|
CAGR 10-Years
27%
|
|
|
Biogaia AB
STO:BIOG B
|
Total Liabilities & Equity
kr2.3B
|
CAGR 3-Years
7%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
|
Bonesupport Holding AB
STO:BONEX
|
Total Liabilities & Equity
kr778.7m
|
CAGR 3-Years
31%
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
|
|
Vitrolife AB
STO:VITR
|
Total Liabilities & Equity
kr16.9B
|
CAGR 3-Years
40%
|
CAGR 5-Years
52%
|
CAGR 10-Years
41%
|
|
|
Probi AB
STO:PROB
|
Total Liabilities & Equity
kr1.6B
|
CAGR 3-Years
7%
|
CAGR 5-Years
5%
|
CAGR 10-Years
26%
|
|
|
BioArctic AB
STO:BIOA B
|
Total Liabilities & Equity
kr1.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
Swedish Orphan Biovitrum AB (publ)
Glance View
Swedish Orphan Biovitrum AB (publ), often referred to as Sobi, is a biopharmaceutical company that has carved a niche in the development and commercialization of innovative treatments for rare diseases, primarily focusing on hematology, immunology, and specialty care. Founded in 2001 and headquartered in Stockholm, Sobi has garnered a reputation for its commitment to improving the lives of patients with complex medical conditions. The company's portfolio includes several key products that address unmet medical needs, particularly in areas such as hemophilia and other inherited disorders. Through strategic partnerships and acquisitions, Sobi has expanded its capabilities, bolstering its research and development pipeline while strengthening its market presence across Europe, North America, and beyond. As an investor, Sobi presents a compelling opportunity in the growing field of rare diseases, bolstered by a robust regulatory framework that often allows for expedited approval processes for groundbreaking therapies. The company’s focus on precision medicine and its dedication to patient-centric care position it well in an industry characterized by high demand and limited competition. With a solid financial foundation and a proactive approach to innovation, Sobi is poised to capture significant market share in a rapidly evolving landscape. Furthermore, with its strategic initiatives in expanding global reach and investing in next-generation therapies, Sobi exemplifies the principles of value investing by aligning long-term growth potential with the increasing need for specialized medical treatments.
See Also
What is Swedish Orphan Biovitrum AB (publ)'s Total Liabilities & Equity?
Total Liabilities & Equity
72.2B
SEK
Based on the financial report for Sep 30, 2024, Swedish Orphan Biovitrum AB (publ)'s Total Liabilities & Equity amounts to 72.2B SEK.
What is Swedish Orphan Biovitrum AB (publ)'s Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
27%
Over the last year, the Total Liabilities & Equity growth was -4%. The average annual Total Liabilities & Equity growth rates for Swedish Orphan Biovitrum AB (publ) have been 16% over the past three years , 17% over the past five years , and 27% over the past ten years .
You don't have any saved screeners yet
